Previous 10 | Next 10 |
Kadmon Holdings (NYSE: KDMN ) and Meiji Seika Pharma ( OTC:MEJHF ) will form a joint venture to exclusively develop and commercialize KD025 in Japan and certain other Asian countries. More news on: Kadmon Holdings, Inc., Meiji Holdings Co., Ltd., Healthcare stocks news, Read more ......
NEW YORK, NY and TOKYO, JAPAN / ACCESSWIRE / December 26, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN), a New York-based biopharmaceutical company, and Meiji Seika Pharma Co., Ltd, a Tokyo-based wholly owned subsidiary of Meiji Holdings Co., Ltd. (TYO: 2269), today announced that the companies h...
This article is part of a series that provides an ongoing analysis of the changes made to Dan Loeb’s 13F stock portfolio on a quarterly basis. It is based on Third Point’s regulatory 13F Form filed on 11/14/2019. Please visit our Tracking Dan Loeb’s Third Point Portfoli...
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
NEW YORK, NY / ACCESSWIRE / November 18, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced the closing of its previously announced underwritten public offering of 29,900,000 shares of common stock for gross proceeds of $101.6 million, before deducting underwriting discounts and estima...
The biotech sector has been one of the high growth spaces over the past decade or so. It remains one of the hottest sectors for stock market investors. When a particular sector has the potential for expansion than even smaller companies, like penny stocks , in the sector have growth opportuniti...
Kadmon Holdings (NYSE: KDMN ) slips 1% premarket on modest volume in reaction to its public offering of 26M common shares at $3.40 per share. Underwriters' over-allotment is an additional 3.9M shares. Gross proceeds should be ~488.4M. More news on: Kadmon Holdings, Inc., Heal...
NEW YORK, NY / ACCESSWIRE / November 13, 2019 / Kadmon Holdings, Inc. (NYSE: KDMN) ("Kadmon") today announced the pricing of an offering of 26,000,000 shares of its common stock at a public offering price of $3.40 per share in an underwritten offering (the "Offering"). The gross proceeds to ...
Kadmon Holdings (NYSE: KDMN ) is off 3.7% postmarket following an announcement it intends to sell shares in a public offering . More news on: Kadmon Holdings, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Gainers: PING +13.3% . SNDL +12.2% . PRSP +8.3% . PSNL +7.5% . TGP +6.5% . More news on: Ping Identity Holding Corp., Sundial Growers Inc., Perspecta Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
- REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States - - Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million - - Sanofi acquisition of Kadm...
NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors, in addition to other IL-...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Kadmon Holdings, Inc. Skyrockets Amid Entering Definitive Merger Agreement with Sanofi Kadmon Holdings, Inc. (NASDAQ: KDMN) surged 73% in premarket trading after entering...